Mum pens book to help children cope with hospital
Bex Grace wrote The Hospital Stay with Frimley Health with input from Frimley Park Hospital's paediatric team.
Bex and her two children were born at the hospital and she is a member of the Maternity Voices Frimley group.
A hospital spokesperson said the book offered "clear, age-appropriate communication and playful storytelling to reduce anxiety and empower children, while supporting parents and carers to guide their children through the experience".
Every illustration is based on real scenes from hospitals at the trust, where 25% of all patients are children.
James Clarke, the trust's chief strategy officer at Frimley Heath NHS Foundation Trust, said: "When I visited the hospital with my own four-year-old, I saw first-hand how many questions young children have and how important it is to help them feel at ease.
"This book is a beautiful example of how we can make our ambitions real for children and families, helping them understand what great care looks like.
"Bex's story is one of giving back, she's a local author, a parent, and a true partner in our mission to make hospital care better for everyone."
The Hospital Stay with Frimley Health is available now on the Frimley Health Charity website, which will receive all profits from book sales.
Follow BBC Surrey on Facebook, on X. Send your story ideas to southeasttoday@bbc.co.uk or WhatsApp us on 08081 002250.
Hospitals in South East given £67m for repairs
Hospital extension welcomes first patients
Frimley Health NHS Foundation Trust
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Measles outbreak leaves several children ‘seriously unwell' as alert issued by NHS
A measles outbreak on Merseyside has left several children 'seriously unwell', a top NHS hospital has warned as it urged people to get vaccinated to help combat the spread of the disease. The rise in cases, according to an alert on Alder Hey Children's Hospital websites, is also driving an increase in patients attending its A&E. In an open letter, published on Monday, the trust's senior directors warned: 'Measles is putting children and young people at risk within our communities and our hospital. Several children are seriously unwell and receiving treatment at Alder Hey Children's Hospital. 'Measles is on the rise amongst our children. We can all help stop it. Get vaccinated now.' It warned that the reason there are more cases of the virus is because fewer people are having the Measles, Mumps and Rubella (MMR) vaccine. The trust said the number of children being treated at Alder Hey hospital over measles is increasing and warned 'children in hospital who are very poorly for another reason, are at higher risk of catching the virus.' In a separate, now-deleted post on its website, Alder Hey said it was experiencing high levels of A&E attendances and that it was 'seeing an increase in children presenting with symptoms of measles.' Measles is highly contagious and, in rare cases, can be fatal. Symptoms usually begin with a runny nose, sneezing, coughing and a high temperature. A measles rash follows a few days after, starting on the face and behind the ears before spreading to the rest of the body. The virus can also cause red, sore eyes. From 26 May to 29 June, there were 133 cases of measles reported to the UK Health Security Agency. Last month UK Health Security Agency published a warning over continued outbreaks and the risk of infection on holiday after data showed 420 measles cases were reported in England between January and May 2025. The majority of those cases, 66 per cent, were in children aged 10 years and under. London had the highest number of cases overall in 2025, with 162. In the four weeks to 5 June, 19 cases, 25 per cent, were reported in the North West and 11 per cent in the West Midlands. #Measles is highly infectious. One person with measles can infect up to 15 others! The best way to protect against measles and stay safe is to have 2 doses of the MMR vaccine. Here's Consultant in Paediatric Public Health at Alder Hey, Rachel Isba, to tell you more: — 🏥 Alder Hey 💙 (@AlderHey) July 6, 2025 Liverpool City Council published a plea on 4 July to parents to get children vaccinated amid a rise in cases across Merseyside. In the warning, Dr Merav Kliner, deputy director for UK Health Security Agency in the North West said: 'With declines in childhood vaccine uptake, including MMR, observed in many countries around the world over the last decade, exacerbated by the COVID-19 pandemic, we are now seeing the impact of this with large measles outbreaks globally including recently in Europe and England last year.' 'Measles is one of the most highly infectious diseases and spreads rapidly among those who are unvaccinated and is often the canary in the coalmine for vaccine preventable diseases. 'We are concerned that this could be an early warning sign of other possible disease outbreaks both globally and here at home, especially over the summer months as families with unvaccinated children and adults travel to countries where diseases are endemic or outbreaks are occurring.'
Yahoo
an hour ago
- Yahoo
Regulator warns of small risk of serious condition in people having RSV jab
The medicines regulator has issued a warning to NHS health staff about a small increased risk of a rare condition affecting the nerves in people vaccinated against respiratory syncytial virus (RSV). Guillain-Barre syndrome is a rare but serious condition which needs urgent treatment in hospital to prevent it progressing. It can affect people's senses, movement, breathing and heartbeat – usually starting in the arms and legs before spreading to other areas. The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug alert for the Abrysvo (made by Pfizer) and Arexvy (GSK) vaccines for RSV after they were linked to 21 suspected cases of Guillain-Barre syndrome in adults aged 60 and over. However, the Commission on Human Medicines still advises that 'the benefits of vaccination against RSV outweigh the small risk of developing Guillain-Barre syndrome in older adults'. In its alert, the MHRA said: 'Healthcare professionals should advise all recipients of Abrysvo and Arexvy that they should be alert to signs and symptoms of Guillain-Barre syndrome and, if they occur, to seek immediate medical attention as it requires urgent treatment in hospital.' It warned staff to be alert to the signs and symptoms of the syndrome. It added that there is currently no evidence of an increased risk of Guillain-Barre syndrome in pregnant women following vaccination with Abrysvo, the only RSV vaccine approved for use during pregnancy. The RSV vaccine helps protect against respiratory syncytial virus, which can make older adults and babies seriously ill. RSV can cause bronchiolitis in babies which can cause breathing problems, while it can cause pneumonia in older people, both of which may require hospital stays. The Pfizer RSV vaccine Abrysvo is currently offered on the NHS to adults aged 75 to 79 and to pregnant women. The GSK RSV vaccine Arexvy is not currently available on the NHS but may be available privately in the UK. Symptoms of Guillain-Barre syndrome can include tingling, numbness or pins and needles in feet and hands, muscle weakness and difficulty moving joints. There may also be problems breathing and drooping face muscles or trouble swallowing or speaking. Up to June 2, the MHRA has received 21 Yellow Card reports of suspected Guillain-Barre syndrome in older adults (aged 75-79 where known) following Abrysvo. This is in the context of over 1.9 million doses of Abrysvo administered, it said. Over the same time period, the MHRA has not received any Yellow Card reports of suspected Guillain-Barre syndrome following Arexvy, however there has been very limited use of this vaccine in the UK to date. In the US, one study suggested Abrysvo and Arexvy were associated with nine and seven excess Guillain-Barre syndrome cases per million vaccine doses administered, respectively.
Medscape
an hour ago
- Medscape
Extra Pneumococcal Dose Can Save Lives in Care Homes
TOPLINE: An additional dose of a pneumococcal vaccine, either 23-valent pneumococcal polysaccharide vaccine (PPV23) or 20-valent pneumococcal conjugate vaccine (PCV20), for new care home residents upon entry could prevent a substantially higher proportion of invasive pneumococcal disease cases and deaths per dose than the single-dose schedule for 65-year-olds, with the PCV20 vaccine demonstrating greater effectiveness over the PPV23 vaccine. METHODOLOGY: Researchers in England conducted an observational surveillance study to evaluate the effect of administering an additional dose of a pneumococcal vaccine, either PPV23 or PCV20, at admission to new residents of older care homes, alongside the routine vaccination. Using national invasive pneumococcal disease surveillance and other data sources, they analysed 121,587 new care home residents (83,271 women and 38,316 men) to estimate the potential number of invasive pneumococcal disease cases and deaths averted over 5 years and calculated the number needed to vaccinate (NNV) to prevent one vaccine-type case and one death. They compared these results with those of 603,109 individuals (aged 65 years) from the general population who had received a single vaccine dose. TAKEAWAY: PPV23 immunisation of all new care home residents would prevent 36% of PPV23-type lifetime cases of invasive pneumococcal disease (NNV, 687) and 48% of deaths (NNV, 1095). Similarly, PCV20 immunisation would prevent 75% of PCV20-type lifetime cases of invasive pneumococcal disease (NNV, 384) and 80% of deaths (NNV, 774). An additional dose of both vaccines could prevent five times more cases and 18 times more deaths than the current immunisation policy for adults aged 65 years. IN PRACTICE: "Protecting older adults, especially those in aged care facilities, from infectious diseases is necessary to reduce morbidity and mortality. Vaccination, including against pneumococcus, is an effective strategy to promote healthy ageing," the author of a commentary wrote. SOURCE: This study was led by Fariyo Abdullahi, MSc, Immunisation and Vaccine Preventable Diseases, UK Health Security Agency, London, England. It was published online on July 01, 2025, in The Lancet Healthy Longevity. LIMITATIONS: The national dataset could not identify individuals in temporary or respite care, potentially leading to an undercount of care home residents. This study relied on invasive pneumococcal disease risk estimates from the older study, which may not have reflected current conditions in England. The NNV might be underestimated as frail residents are less likely to receive invasive investigations. DISCLOSURES: The Immunisation and Vaccine Preventable Diseases Division provided vaccine manufacturers with postmarketing surveillance reports on pneumococcal and meningococcal infections, with cost recovery charges applied. One author reported performing contract research for pharmaceutical companies on behalf of St George's University of London and the UK Health Security Agency without personal remuneration. The other authors reported having no competing interests. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
